Bezares S, Amador ML, Castellano D, Trigo JM, Cortés-Funes H, Colomer R. Combined treatment with biphosphonates, low-dose chemotherapy, and trastuzumab in receptor-negative breast cancer patients with bone marrow involvement. Eur J Intern Med. 2001;12(5):462-3

Colomer R, Shamon LA, Tsai MS, Lupu R. Herceptin: from the bench to the clinic. Cancer Invest. 2001;19(1):49-56.

García Carbonero R, Mayordomo JI, Tornamira MV, López Brea M, Rueda A, Guillem V, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst. 2001;93(1):31-8

Grávalos C, Rodríguez Dapena S, Alcalde J, Martínez Pueyo JI, Castells V, Ruiz López P. Desarrollo de una vía clínica para mejorar el proceso de tratamiento adyuvante del carcinoma de colon. Rev Calid Asist. 2001;16(3):173-80

Grávalos C, Rodríguez Dapena S, Alcalde J, Martínez Pueyo JI, Castells V, Ruiz López P. Evaluación de dos procesos de carcinoma de colon en oncología médica. Rev Calid Asist. 2001;16(3):183-92

López Medrano F, Sánchez Muñoz A, Sánchez Sánchez V, Costa Pérez-Herrero J.R. Cardiotoxicidad por 5-fluorouracilo: ¿Isquemia o toxicidad miocárdica? Rev Clin Esp. 2001;201(2):106-7

Mendiola C, Povedad A, González A, Cassinello J. La oncología médica en el tratamiento de la enfermedad avanzada del carcinoma de endometrio. Cienc Ginekol. 2001;5(6):266-76

Menéndez JA, Del Mar Barbacid M, Montero S, Sevilla E, Escrich E, Solanas M, et al. Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells. Eur J Cancer. 2001;37(3):402-13

Menéndez P, Prósper F, Bueno C, Arbona C, San Miguel JF, García Conde J, et al. Sequential analysis of CD34+ and CD34- cell subsets in peripheral blood and leukapheresis products from breast cancer patients mobilized with SCF plus G-CSF and cyclophosphamide. Leukemia. 2001;15(3):430-9 [doi

Montero S, Guzmán C, Vargas C, Ballestín C, Cortés-Funes H, Colomer R. Prognostic value of cytosolic p53 protein in breast cancer. Tumour Biol. 2001;22(5):337-44

Paz-Ares L, Olivia E, Carey RW, Smith MR. Skin lesions in malignancy. Case 2. Skin metastases from prostate adenocarcinoma. J Clin Oncol. 2001;19(7):2099-100 [doi]

Pérez Gracia JL, Colomer R, Esteban E, Barceló R, Benavides M, Puertas J, et al. High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma: a Phase II multicentric trial. Cancer. 2001;92(10):2508-16.

Pérez Gracia JL, Colomer R, Ruiz Casado A, Arcediano A, Tornamira MV, Gómez Martin C, et al. High-dose mitoxantrone and cyclophosphamide without stem cell support in high-risk and advanced solid tumors: a phase I trial. Bone Marrow Transplant. 2001;27(2):117-23




Bellmunt J, Albanell J, Paz-Ares L, Climent MA, González Larriba JL, Carles J, et al.; Spanish Oncology Genitourinary Group. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer. 2002;95(4):751-7 [doi]

Cortés-Funes H. Antiangiogenesis agents. Drugs Today. 2002;38(Suppl. 1):11-9

De la Rosa F, García Carbonero R, Passas J, Rosino A, Lianes P, Paz-Ares L. Primary cisplatin, methotrexate and vinblastine chemotherapy with selective bladder preservation for muscle invasive carcinoma of the bladder: long-term followup of a prospective study. J Urol. 2002;167(6):2413-8 [doi]

García Carbonero R, Paz-Ares L. Antibiotics and growth factors in the management of fever and neutropenia in cancer patients. Curr Opin Hematol. 2002;9(3):215-21 [doi]

Garcia del Muro X, Marcuello E, Gumá J, Paz-Ares L, Climent MA, Carles J, et al. Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. Br J Cancer. 2002;86(3):326-30 [doi]

Hitt R, Paz-Ares L, Brandáriz A, Castellano D, Peña C, Millán JM, et al. Induction chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for squamous cell carcinoma of the head and neck: long-term results of a phase II trial. Ann Oncol. 2002;13(10):1665-73.

Hornedo J, Solá C, Solano C, López JJ, Alonso S, Lluch A, et al. The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period. Bone Marrow Transplant. 2002;29(9):737-43.

Menéndez JA, Ropero S, del Barbacid MM, Montero S, Solanas M, Escrich E, et al. Synergistic interaction between vinorelbine and gamma-linolenic acid in breast cancer cells. Breast Cancer Res Treat. 2002;72(3):203-19.

Paz-Ares L, Ciruelos E, García Carbonero R, Castellano D, Lopez Martín A, Cortés-Funes H. Pemetrexed in bladder, head and neck, and cervical cancers. Semin Oncol. 2002;29(6 Suppl 18):69-75.




Amador ML, Jimeno J, Paz-Ares L, Cortés-Funes H, Hidalgo M. Progress in the development and acquisition of anticancer agents from marine sources. Ann Oncol. 2003;14(11):1607-15 [doi]

Aparicio J, García del Muro X, Maroto P, Paz-Ares L, Alba E, Sáenz A, et al.; Spanish Germ Cell Cancer Cooperative Group (GG). Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol. 2003;14(6):867-72 [doi]

Castellano D, Hitt R, Ciruelos E, Cortés-Funes H, Colomer R. Biweekly vinorelbine and gemcitabine: a phase I dose-finding study in patients with advanced solid tumors. Ann Oncol. 2003;14(5):783-7

Cortés-Funes H. Conclusion. Br J Cancer. 2003;89(Suppl. 2):S24

Cortés-Funes H, Soto Parra H. Extensive experience of disease control with gefitinib and the role of prognostic markers. Br J Cancer. 2003;89 Suppl 2:S3-8

Durán I, Robles L, Paz-Ares L, Cortés-Funes H. Tratamiento del cáncer de testículo recurrente.  Revis Cancer. 2003;17(5):219-28

Hitt R, Jimeno A, Castellano D, Cortés-Funes H. Unusual response to gemcitabine in a case of peritoneal malignant fibrous histiocytoma. Anticancer Drugs. 2003;14(8):663-4.

Jimeno A, Ciruelos EM, Castellano D, Caballero B, Rodriguez Peralto JL, Cortés-Funes H. Radiation recall dermatitis induced by pegylated liposomal doxorubicin. Anticancer Drugs. 2003;14(7):575-6.

Paz-Ares L, Bezares S, Tabernero JM, Castellanos D, Cortés-Funes H. Review of a promising new agent–pemetrexed disodium. Cancer. 2003;97(8 Suppl):2056-63.

Sánchez Muñoz A, Hitt R, Artiles V, López A, Hernández R, Cortés-Funes H, et al. Primary aortic sarcoma with widespread vascular embolic metastases. Eur J Intern Med. 2003;14(4):258-61

Sánchez Muñoz A, Grávalos Castro C, Colomer Bosch R, García Velasco A, García JP, Cortés-Funes H. Diseminación metastásica cutaneoganglionar generalizada como manifestación inicial de la recidiva de un adenocarcinoma gástrico. Rev Clin Esp. 2003;203(12):597-8

Sánchez Muñoz A, López Medrano F, Artiles Valle V, Jimeno Largo A, González Billalabeitia E. Isquemia intestinal aguda extensa en el seno de carcinoma de colon con recidiva local. Rev Clin Esp. 2003;203(10):489-90

Sánchez Muñoz A, Mendiola Fernández C, García Velasco A, Hernando Polo S, Hernández Sánchez L, Pérez-Regadera J, Cortés-Funes H. Metástasis peritoneales en el cáncer de mama: Un patrón típico de diseminación del carcinoma lobulillar infiltrante. Oncologia. 2003;26(6):58-62




Amador ML, Jimeno A, Hitt R, Cortés-Funes H, Colomer R. Dose and dose intensity effect of adjuvant anthracycline-based chemotherapy in early breast cancer: a retrospective analysis. Am J Clin Oncol. 2004;27(3):269-73

Cortés-Funes H. Gefitinib (IRESSA) in patients unsuitable for chemotherapy. Europ Respir Rev. 2004;13(93):137-41

De Jonge MJ, Droz JP, Paz-Ares L, van Oosterom AT, de Wit R, Chollet P, et al.; EORTC-New Drug Development Group/New Drug Development Program. Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors. Invest New Drugs. 2004;22(3):329-33 [doi]

Douillard JY, Peschel C, Shepherd F, Paz-Ares L, Arnold A, Davis M, et al. Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer. Lung Cancer. 2004;46(3):361-8 [doi]

Grávalos Castro C, Murillo González T, Quintela Fandino M. Metástasis hepáticas de cáncer colorrectal: Quimioterapia intraarterial.  Revis Cancer. 2004;18(4):226-38

Hitt R, Jimeno A, Millán JM, Castellano D, Cortés-Funes H. Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck. Cancer. 2004;101(4):768-75.

Hitt R, Jimeno A, Rodríguez Pinilla M, Rodríguez Peralto JL, Millán JM, López Martín A, et al. Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors. Br J Cancer. 2004;91(12):2005-11.

Jimeno A, Amador ML, González Cortijo L, Tornamira MV, Ropero S, Valentín V, et al. Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma. Cancer. 2004;100(9):1833-42.

Jimeno A, García Velasco A, Del Val O, González Billalabeitia E, Hernando S, Hernández R, et al. Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer. 2004;100(11):2462-9.

Ropero S, Menéndez JA, Vázquez Martín A, Montero S, Cortés-Funes H, Colomer R. Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma. Breast Cancer Res Treat. 2004;86(2):125-37

Sánchez Muñoz A, González Martín A, Mendiola Fernández C. Factores pronósticos del cáncer de ovario. Revis Cancer. 2004;18(1):12-22

Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C, et al.; European Germ Cell Cancer Consensus Group. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol. 2004;15(9):1377-99 [doi]

Tabernero J, Paz-Ares L, Salazar R, Lianes P, Guerra J, Borrás J, et al. Incidence of contralateral germ cell testicular tumors in South Europe: report of the experience at 2 Spanish university hospitals and review of the literature. J Urol. 2004;171(1):164-7 [doi]




Aparicio J, Germà JR, García del Muro X, Maroto P, Arranz JA, Sáenz A, et al.; Second Spanish Germ Cell Cancer Cooperative Group. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol. 2005;23(34):8717-23 [doi]

Camps C, Felip E, Sánchez JM, Massuti B, Artal A, Paz-Ares L, et al.; Spanish Lung Cancer Group. Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer. Ann Oncol. 2005;16(4):597-601 [doi]

Contreras Martínez J. Definición y áreas de la calidad de vida en Oncología. OncologIa 2005;28(3):17-19

Cortés-Funes H, Gómez C, Rosell R, Valero P, García-Girón C, Velasco A, et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol. 2005;16(7):1081-6.

Gómez Martín C, Rubio Viqueira B, Hidalgo M. Current status of mammalian target of rapamycin inhibitors in lung cancer. Clin Lung Cancer. 2005;7 Suppl 1:S13-8.

Hitt R, Ciruelos E, Amador ML, Benito A, Sánchez JJ, Ballestín C, et al. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. Eur J Cancer. 2005;41(3):453-60.

Hitt R, López Pousa A, Martínez Trufero J, Escrig V, Carles J, Rizo A, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005;23(34):8636-45.

Jimeno A, Hitt R, Quintela Fandino M, Cortés-Funes H. Phase II trial of vinorelbine tartrate in patients with treatment-naive metastatic melanoma. Anticancer Drugs. 2005;16(1):53-7

Leighl NB, Paz-Ares L, Douillard JY, Peschel C, Arnold A, Depierre A, et al. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol. 2005;23(12):2831-9 [doi]

Paz-Ares L, Neciosup S. Tratamiento de quimioterapia del cáncer avanzado de vejiga.  Revis Cancer. 2005;19(3):153-62

Pérez Escutia MA, Samper Ots P, Cabeza Rodríguez MA. Prevención y tratamiento de la toxicidad digestiva. Oncologia. 2005;28(2):47-57

Quintela Fandino M, Grávalos C, González E, García Velasco A, Cortés-Funes H. Irinotecan (CPT-11)-based chemotherapy as induction treatment for advanced colorectal cancer. Anticancer Drugs. 2005;16(1):31-8

Samper Ots PM, Pérez Escutia MA, Cabezas MA. Toxicidad en tratamientos de abdomen y pelvis: Tipo de toxicidad y escalas de valoración. Oncologia. 2005;28(2):35-41

Sánchez Muñoz A, Aguado JM, López Martín A, López Medrano F, Lumbreras C, Rodríguez FJ, et al. Usefulness of antibiotic-lock technique in management of oncology patients with uncomplicated bacteremia related to tunneled catheters. Eur J Clin Microbiol Infect Dis. 2005;24(4):291-3

Sastre J, Paz-Ares L, Carcas A, Alfonso R, Grávalos C, Frías J, et al. A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours. Cancer Chemother Pharmacol. 2005;55(5):453-60 [doi]

Scagliotti GV, Kortsik C, Dark GG, Price A, Manegold C, Rosell R, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res. 2005 Jan;11(2 Pt 1):690-6

Valentín Maganto V, Camps Herrero C, Carulla Torrent J, Cassinello Espinosa J, Dorta Delgado J, Jara Sánchez C, et al. Tolerabilidad y efectividad del citrato de fentanilo oral transmucosa en el tratamiento a largo plazo del dolor irruptivo en pacientes oncológicos. Estudio ECODIR. Clin Transl Oncol. 2005;7(5):205-12.

Valentín Maganto V, Murillo González M. Dilemas al final de la vida. Clin Transl Oncol. 2005;7(7):285-94.




Cortés-Funes H. Capecitabine for the oral treatment of metastatic breast cancer. Womens Health (Lond). 2006;2(6):805-17

Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329-38 [doi]

Fernández Bustamante A, Ibáñez V, Alfaro JJ, De Miguel E, Germán MJ, Mayo A, et al. High-frequency jet ventilation in interventional bronchoscopy: factors with predictive value on high-frequency jet ventilation complications. J Clin Anesth. 2006;18(5):349-56

García Carbonero R, Paz-Ares L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32(6):676-81 [doi]

Hitt R. Induction chemotherapy in head and neck cancer. Ann Oncol. 2006;17 Suppl 10:x42-4.

Hitt R, Amador ML, Quintela Fandino M, Jimeno A, Del Val O, Hernando S, et al. Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Cancer. 2006;106(1):106-11.

Hitt R, Echarri MJ. Molecular biology in head and neck cancer. Clin Transl Oncol. 2006;8(11):776-9.

Hitt R, Martín P, Hidalgo M. Cetuximab in squamous cell carcinoma of the head and neck. Future Oncol. 2006;2(4):449-57.

Jimeno A, Arcediano A, Bazares S, Amador ML, González Cortijo L, Ciruelos E, et al. Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia. Clin Transl Oncol. 2006;8(12):889-95

López Encuentra A, Martín de Nicolás JL, Paz-Ares L, Bartolomé A; Grupo Cooperativo de Carcinoma Broncogénico del Hospital Universitario 12 de Octubre de Madrid. Tratamiento multimodal en el carcinoma broncogénico no microcítico (N2) clínico: cuál es la respuesta? Arch Bronconeumol. 2006;42(3):154 [doi]

López Medrano F, Del Val Muñoz O, Sánchez Muñoz A, San Juan R, Grávalos C. Mujer con antecedentes oncológicos y dolor en el muslo derecho: Una infección diseminada por contigüidad. Enferm Infecc Microbiol Clin. 2006;24(2):129-30

Mendoza Sánchez MC, Ruiz Contreras J, Vivanco JL, Fernández Carrión F, Baro Fernández M, Ramos JT, et al. Respiratory virus infections in children with cancer or HIV infection. J Pediatr Hematol Oncol. 2006;28(3):154-9.

Paz-Ares L, Douillard JY, Koralewski P, Manegold C, Smit EF, Reyes JM, et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2006;24(9):1428-34.

Quintela Fandino M, Hitt R, Medina PP, Gamarra S, Manso L, Cortés-Funes H, et al. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol. 2006;24(26):4333-9.

Quintela Fandino M, López JM, Hitt R, Gamarra S, Jimeno A, Ayala R, et al. Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support. J Clin Oncol. 2006;24(22):3611-8

Valentín Maganto V, Murillo González M, Valentín Moreno M. Analgésicos no opiáceos en el tratamiento del dolor oncológico. Revis Cancer. 2006;20(3):99-114




Álvarez Cabellos R, García Carbonero R, García Lacalle C, Gómez P, Tercero A, Sánchez D, et al. Fluorouracil-based chemotherapy in patients with gastrointestinal malignancies: influence of nutritional folate status on toxicity. J Chemother. 2007;19(6):744-9 [doi]

Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, Guillem V, et al.; Spanish Oncology Genitourinary Group. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol. 2007;18(3):522-8 [doi]

Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol. 2007;25(19):2747-54 [doi]

Cortés-Funes H. Capecitabine for the oral treatment of metastaticbreast cáncer. Women Health. 2006;2(6):805-17

Cortés-Funes H, Coronado C. Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol. 2007;7(2):56–60

Díaz Padilla I, Paz-Ares Rodríguez L. Molecular targetedtherapy in prostate Cancer. Cancer Chemother Rev. 2007;2(1):10-16

González EL, Pérez Escutia MA, Pérez-Regadera Gómez JF. -Radioquimioterapia del paciente paliativo. Revis Cancer. 2007;21(1):22-30

Grávalos C, Cassinello J, Fernández Rañada I, Holgado E. Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer. Clin Colorectal Cancer. 2007;6(10):691-9

López Martín A, Ballestín C, García Carbonero R, Castaño A, López Ríos F, López Encuentra A, et al. Prognostic value of KIT expression in small cell lung cancer. Lung Cancer. 2007;56(3):405-13

Manso L, Álvarez E, Quintela M, Cortés-Funes H, Hitt R. Primary pulmonary artery sarcoma: report of three cases and review of the literature. Clin Lung Cancer. 2007;8(4):277-81

Paz-Ares L, Rivera Herreros F, Díaz Rubio E, García M, Casado E, Cubedo R, et al. Phase II study of trabectedin in pretreated patients with advanced colorectal cancer. Clin Colorectal Cancer. 2007;6(7):522-8

Santoro A, O’Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol. 2008;3(7):756-63 [doi]




Folprecht G, Tabernero J, Köhne CH, Zacharchuk C, Paz-Ares L, Rojo F, et al. Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer. Clin Cancer Res. 2008;14(1):215-23 [doi]

Gallego Álvarez M, Sanz Fernández MC, Noguero Meseguer MR, Sancho Pérez B, Carpintero Franco R, Segovia Blázquez B, et al. Linfomas primarios de mama. Presentación de nuestra casuística y revisión de la literatura científica. Progr Obstetr Ginecol. 2008;51(1):47-52

González Billalabeitia E, Quintela Fandino M, Alemany I, López Alonso G, Ruiz Ollero A, Martínez Tello F, et al. Coexistence of two rare sarcomas: primary leiomyosarcoma of bone and epithelioid hemangioendothelioma of the liver. Sarcoma. 2008;2008:416085

Grávalos C. Nuevas dianas terapéuticas en el tratamiento del cáncer de páncreas. Revis Cancer. 2008;22(4):167-76

Grávalos C, García Sánchez L, Hernández M, Holgado E, Álvarez N, García Escobar I, et al. Surgical resection of a solitary pancreatic metastasis from colorectal cancer: a new step to a cure? Clin Colorectal Cancer. 2008;7(6):398-401.

Grávalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523-9

Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol. 2008;53(3):497-513 [doi]

Narváez A, Rubiños C, Cortés-Funes F, Gómez R, García A. Valoración de la eficacia de una terapia grupal cognitivo-conductualen la imagen corporal, autoestima, sexualidad y malestar emocional (Ansiedad y depresión) en pacientes de cáncer de mama. Psicooncologia. 2008;5(1):93-102

Pardo B, Paz-Ares L, Tabernero J, Ciruelos E, García M, Salazar R, et al. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors. Clin Cancer Res. 2008;14(4):1116-23 [doi]

Paz-Ares L, García del Muro X, Grande E, González P, Brosa M, Díaz S. Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib. Clin Transl Oncol. 2008;10(12):831-9

Paz-Ares L, Ross H, O’Brien M, Riviere A, Gatzemeier U, Von Pawel J, et al. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer. 2008;98(10):1608-13.




Capdevila Castillón J, Crespo G, García Carbonero R, Vilar E, Jiménez Lacave A, Martínez del Prado MP, et al. Results of the gastroenteropancreatic NETs Spanish registry in the 2001-2009 period. Neuroendocrinology. 2009;90(1):102

Castellano D, Del Muro XG, Pérez Gracia JL, González Larriba JL, Abrio MV, Ruiz MA, et al. Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population. Ann Oncol. 2009;20(11):1803-12 [doi

Cortés-Funes H. The role of antiangiogenesis therapy: bevacizumab and beyond. Clin Transl Oncol. 2009;11(6):349-55

Fumoleau P, Cortés-Funes H, Taleb AB, Chan S, Campone M, Pouget JC, et al. Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy. Am J Clin Oncol Cancer Clin Trials. 2009;32(4):375-80

Garrido Laguna I, Amador ML, Ruiz J, Cortés-Funes H. Acute ischaemic cerebrovascular attack secondary to infusional 5-fluoruracil and cisplatin in a patient with advanced gastric cancer. Clin Transl Oncol. 2009;11(3):183-5

González Billalabeitia E, Calzas J, Castellano D, Mendiola C, Bezares S, Valentín V, et al. Long-term follow-up of an anthracycline-containing metronomic chemotherapy schedule in advanced breast cancer. Breast J. 2009;15(5):551-3

Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009;10(8):757-63

Grávalos C, García Escobar I, García Alfonso P, Cassinello J, Malón D, Carrato A. Adjuvant chemotherapy for stages II, III and IV of colon cancer. Clin Transl Oncol. 2009;11(8):526-33

Iglesias Docampo L, Ghanem Cañete I, Homet Moreno B, Sánchez Torres JM. Terapias biológicas en cáncer de pulmón. Revis Cancer. 2009;23(6):225-36

Martín Algarra S, Espinosa E, Rubió J, López López JJ, Manzano JL, Carrión LA, et al. Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma. Eur J Cancer. 2009;45(5):732-5 [doi]

Perea J, Justo I, Álvaro E, Lomas M, Díaz Tasende J, Marín JC, et al. Surgical management of hereditary colorectal cancer: surgery based on molecular analysis and family history. Rev Esp Enferm Dig. 2009;101(8):536-40

Robledo C, García JL, Caballero D, Conde E, Arranz R, Flores T, et al. Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas. Cancer. 2009;115(16):3728-37

Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. New Engl J Med. 2009;361(10):958-67

Sepúlveda Sánchez JM, Martínez Montero JC, Díez Lobato R, Hernández Laín A, Cabello A, Ramos A, et al. Classification of oligodendroglial tumors based on histopathology criteria is a significant predictor of survival–clinical, radiological and pathologic long-term follow-up analysis. Clin Neuropathol. 2009;28(1):11-20


Castellano D, De la Rosa F, Rodríguez Antolín A, Villacampa F, Sepúlveda J, Ghanem I, et al. Sunitinib therapy for patients with Advanced Renal Cell Carcinoma (ARCC): Analysis for safety and activity on single institution experience: Favourable overall survival according MSKCC-group risk. Urology. 2009;74(4):S113 [Congress of the Societe Internationale d’Urologie (30. Shanghai. 2009)]




Agulló Ortuño MT, López Ríos F, Paz Ares L. Lung cancer genomic signatures. J Thorac Oncol. 2010;5(10):1673-91.

Ciruelos EM, Cortés J, Cortés-Funes H, Mayordomo JI, Bermejo B, Ojeda B, et al. Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial). Ann Oncol. 2010;21(7):1442-7.

Durán I, García Velasco A, Ballestín C, García E, Martínez Tello F, Pond GR, et al. Expression of EGFR, HER-2/neu and KIT in germ cell tumours. Clin Transl Oncol. 2010;12(6):443-9.

Gómez Martín C, Rodríguez A, Malón D, Cortés-Funes H. Biliary cystadenocarcinoma with mesenchymal stroma. Clin Transl Oncol. 2010;12(3):234-7.

Grávalos C, Cassinello J, García Alfonso P, Jimeno A. Integration of panitumumab into the treatment of colorectal cancer. Crit Rev Oncol Hematol. 2010;74(1):16-26.

Grávalos C, Grande E, Gasent JM. The potential role of sunitinib in gastrointestinal cancers other than GIST. Crit Rev Oncol Hematol. 2010;76(1):36-43.

Grávalos Castro C, Maurel Santasusana J, Rivera Herrero F, Salazar Soler R, Sevilla García I, Sastre Valera J, et al. SEOM clinical guidelines for the adjuvant treatment of colorectal cancer. Clin Transl Oncol. 2010;12(11):724-8.

Homet Moreno B, Garralda Cabanas E, Hitt R. Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas. Clin Transl Oncol. 2010;12(7):468-72.

Homet B, Hitt R, Ghanem I, Cortés-Funes H. Diagnosis of unknown primary cancer based on molecular techniques may influence therapeutic approach and improve survival. Clin Transl Oncol. 2010;12(8):574-5.

Paz-Ares L, Del Muro JG, Grande E, Díaz S. A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System. J Clin Pharm Ther. 2010;35(4):429-38.

Vaz Salgado MAM, García CG, López Martín JA, Guerra E, Benito A, Sepúlveda JM, et al. Porocarcinoma: Clinical evolution. Dermatol Surg. 2010;36(2):264-7.